TMS denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied TMS as "Experimental" — and Why That Characterization Is Outdated

When UnitedHealthcare labels TMS "experimental" or "investigational," it is invoking a coverage exclusion that typically requires a treatment to have insufficient peer-reviewed evidence or to lack regulatory clearance. For TMS, this characterization conflicts with the treatment's FDA clearance status and its recognition by applicable major psychiatric organizations. The denial most often reflects an outdated policy version, an incorrectly coded claim, or a reviewer applying a blanket experimental exclusion without checking current clearance status.

The relevant question in your appeal is not whether TMS is new — it is whether UHC's own current coverage policy, read accurately, classifies TMS as experimental for your specific cleared indication. In many cases, UHC's policy does cover TMS for the cleared indication; the denial is a misapplication rather than a correct policy decision.

## The Federal Appeal Framework

Under ACA §2719, non-grandfathered plans must provide internal appeal and independent external review — external review is particularly powerful for experimental/investigational denials because independent reviewers assess whether the treatment meets recognized clinical standards, which TMS does for its cleared indications. Under ERISA §503, employer-sponsored plans must provide a full-and-fair review with written reasoning. The external-review window is generally roughly four months after the internal denial. An expedited appeal is available when your clinician certifies that delay would seriously jeopardize your health.

## What to Gather

• FDA clearance documentation for the specific TMS device. Obtain the 510(k) clearance letter from your prescriber or the device manufacturer. This directly rebuts the "lacks regulatory clearance" prong of most experimental exclusions.
• UHC's current coverage policy for TMS. Request it by name. Compare the policy's definition of "experimental" to TMS's current regulatory and clinical evidence status.
• Recognition by applicable guideline organizations. Your prescriber's letter should reference the relevant professional organization (such as the applicable psychiatric or neurology society) that has incorporated TMS into its treatment guidelines, without citing specific statistics.
• Diagnosis confirmation and severity documentation. Formal records establishing the diagnosis and that it falls within the cleared indication.
• Prior treatment history. Documentation of prior antidepressant trials — names, dates, outcomes — establishing the treatment-resistant profile that the cleared indication contemplates.
• Prescriber medical-necessity letter. A signed letter specifically addressing UHC's experimental characterization, citing the FDA clearance and applicable professional recognition.

## Criteria-Mapping Structure

Map each element of UHC's experimental/investigational definition against the evidence: regulatory status, evidence base, guideline recognition. For each element the denial cites, provide the documentary rebuttal. External reviewers are required to apply recognized clinical standards, and a well-organized rebuttal of each experimental criterion is your strongest argument.

## Next Step

File the internal appeal in writing immediately. Attach the FDA clearance letter and the criteria-mapping rebuttal. If denied internally, invoke external review promptly in writing.